PMC:7408073 / 91812-92096 JSONTXT

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T184","span":{"begin":258,"end":261},"obj":"Body_part"}],"attributes":[{"id":"A184","pred":"uberon_id","subj":"T184","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"}],"text":"A second report showed significantly lower values of Ang II, (interquartile range) between 40–150 ng/mL (non-survivors with placebo) and 5–20 pg/mL (survivors with placebo) (see Supplementary Data [134]), suggesting that they used different protocols of the RAS peptide determination."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3226","span":{"begin":53,"end":59},"obj":"Gene"}],"attributes":[{"id":"A3226","pred":"tao:has_database_id","subj":"3226","obj":"Gene:24179"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"A second report showed significantly lower values of Ang II, (interquartile range) between 40–150 ng/mL (non-survivors with placebo) and 5–20 pg/mL (survivors with placebo) (see Supplementary Data [134]), suggesting that they used different protocols of the RAS peptide determination."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1122","span":{"begin":0,"end":1},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T1123","span":{"begin":142,"end":144},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T1124","span":{"begin":262,"end":269},"obj":"http://purl.obolibrary.org/obo/PR_000018263"}],"text":"A second report showed significantly lower values of Ang II, (interquartile range) between 40–150 ng/mL (non-survivors with placebo) and 5–20 pg/mL (survivors with placebo) (see Supplementary Data [134]), suggesting that they used different protocols of the RAS peptide determination."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T398","span":{"begin":57,"end":59},"obj":"Chemical"},{"id":"T65534","span":{"begin":258,"end":261},"obj":"Chemical"},{"id":"T400","span":{"begin":262,"end":269},"obj":"Chemical"}],"attributes":[{"id":"A1191","pred":"chebi_id","subj":"T398","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A28123","pred":"chebi_id","subj":"T65534","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"},{"id":"A19194","pred":"chebi_id","subj":"T400","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"}],"text":"A second report showed significantly lower values of Ang II, (interquartile range) between 40–150 ng/mL (non-survivors with placebo) and 5–20 pg/mL (survivors with placebo) (see Supplementary Data [134]), suggesting that they used different protocols of the RAS peptide determination."}

{"project":"LitCovid-sentences","denotations":[{"id":"T445","span":{"begin":0,"end":284},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"A second report showed significantly lower values of Ang II, (interquartile range) between 40–150 ng/mL (non-survivors with placebo) and 5–20 pg/mL (survivors with placebo) (see Supplementary Data [134]), suggesting that they used different protocols of the RAS peptide determination."}

{"project":"2_test","denotations":[{"id":"32708755-28877748-20678996","span":{"begin":198,"end":201},"obj":"28877748"}],"text":"A second report showed significantly lower values of Ang II, (interquartile range) between 40–150 ng/mL (non-survivors with placebo) and 5–20 pg/mL (survivors with placebo) (see Supplementary Data [134]), suggesting that they used different protocols of the RAS peptide determination."}